RemeGen Co., Ltd. released its Monthly Return for the period ended 31 March 2026, indicating no changes to either authorised/registered or issued share capital across its dual-listed share classes.

Key Takeaways

1. Capital Structure • Authorised / registered share capital remained at 564.48 million shares, split between 208.58 million H-shares (par value RMB 1) and 355.90 million A-shares (par value RMB 1). No additions or cancellations were reported during the month.

2. Issued Shares and Treasury Position • Issued H-shares stood unchanged at 208.58 million, with no treasury holdings. • Issued A-shares were steady at 355.70 million; treasury shares were unchanged at 0.19 million, leaving total A-shares at 355.90 million. • The company recorded zero movements in issued or treasury shares for both H- and A-share classes during March.

3. Public Float Compliance • RemeGen confirmed it met the Hong Kong Stock Exchange’s minimum 5 percent public float requirement for its H-shares as of 31 March 2026.

4. Outstanding Equity Incentives • Under the 2022 and 2023 A-Share Incentive Schemes, 2.31 million restricted A-shares remain available for future issuance or transfer. No new shares were granted, lapsed or vested in March.

The filing underscores RemeGen’s stable share base and adherence to listing rules, with no dilution or treasury share activity recorded in the month under review.